Samine Jessica Isaac

Samine Jessica Isaac

Auto-generated profile, based on publicly available information

Samine Jessica Isaac

University of Trento

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CICarmela Irene
Carmela Irene
LFLaura Fantappiè
Laura Fantappiè
ECElena Caproni
Elena Caproni
FZFrancesca Zerbini
Francesca Zerbini
AAAndrea Anesi
Andrea Anesi
GGGuido Grandi
Guido Grandi
Significance: Thanks to their potent built-in adjuvanticity, bacterial outer membrane vesicles (OMVs) represent an attractive vaccine platform. However, their full-blown exploitation relies on the availability of efficient engineering strategies. This work provides strong experimental evidence that OMVs can be successfully decorated with heterologous antigens by channeling them to the lipoprotein transport machinery. Not only did lipidated antigens accumulate in the vesicular compartment at high levels but they also interfered with the acylation process of lipid A, thus substantially reducing the lipopolysaccharide-mediated reactogenicity, a major hurdle for vaccine applications. The approach was validated with 5 Staphylococcus aureus antigens, and mice immunized with engineered OMVs were completely protected against S. aureus challenge, paving the way for development of vaccines against this important pathogen.

7 November 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
AGAlberto Grandi
Alberto Grandi
MTMichele Tomasi
Michele Tomasi
IZIlaria Zanella
Ilaria Zanella
LGLuisa Ganfini
Luisa Ganfini
ECElena Caproni
Elena Caproni
GGGuido Grandi
Guido Grandi
Introduction Bacterial Outer Membrane Vesicles (OMVs) are naturally produced by all Gram-negative bacteria and thanks to their plasticity and unique adjuvanticity are emerging as an attractive vaccine platform. To test the applicability of OMVs in cancer immunotherapy we decorated them with either one or two protective epitopes present in the B16F10EGFRvIII cell line and we tested the protective activity of OMV immunization in C57BL/6 mice challenged with B16F10EGFRvIII. Materials and methods The 14 amino acid B cell epitope of human epidermal growth factor receptor variant III (EGFRvIII) and the mutation-derived CD4+ T cell neo-epitope of kif18b gene (B16-M30) were used to decorate OMVs either alone or in combination. C57BL/6 were immunized with the OMVs and then challenged with B16F10EGFRvIII cells. Immunogenicity and protective activity was followed by measuring anti-EGFRvIII antibodies, M30-specific T cells, tumor infiltrating cell population and tumor growth. Results Immunization with engineered EGFRvIII-OMVs induced a strong inhibition of tumor growth after B16F10EGFRvIII challenge. Furthermore, mice immunized with engineered OMVs carrying both EGFRvIII and M30 epitopes were completely protected from tumor challenge. Immunization was accompanied by induction of high anti-EGFRvIII antibody titers, M30-specific T cells and infiltration of CD4+ and CD8+ T cells at the tumor site. Conclusion OMVs can be decorated with tumor antigens and can elicit antigen-specific, protective anti-tumor responses in immunocompetent mice. The synergistic protective activity of multiple epitopes simultaneously administered with OMVs makes the OMV platform particularly attractive for cancer immunotherapy.

26 October 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AGAlberto Grandi
Alberto Grandi
LFLaura Fantappiè
Laura Fantappiè
CICarmela Irene
Carmela Irene
SVSilvia Valensin
Silvia Valensin
MTMichele Tomasi
Michele Tomasi
GGGuido Grandi
Guido Grandi
Human FAT1 is overexpressed on the surface of most colorectal cancers (CRCs) and in particular a 25 amino acid sequence (D8) present in one of the 34 cadherin extracellular repeats carries the epitope recognized by mAb198.3, a monoclonal antibody which partially protects mice from the challenge with human CRC cell lines in xenograft mouse models. Here we present data in immune competent mice demonstrating the potential of the D8-FAT1 epitope as CRC cancer vaccine. We first demonstrated that the mouse homolog of D8-FAT1 (mD8-FAT1) is also expressed on the surface of CT26 and B16F10 murine cell lines. We then engineered bacterial outer membranes vesicles (OMVs) with mD8-FAT1 and we showed that immunization of BALB/c and C57bl6 mice with engineered OMVs elicited anti-mD8-FAT1 antibodies and partially protected mice from the challenge against CT26 and EGFRvIII-B16F10 cell lines, respectively. We also show that when combined with OMVs decorated with the EGFRvIII B cell epitope or with OMVs carrying five tumor-specific CD4+ T cells neoepitopes, mD8-FAT1 OMVs conferred robust protection against tumor challenge in C57bl6 and BALB/c mice, respectively. Considering that FAT1 is overexpressed in both KRAS+ and KRAS− CRCs, these data support the development of anti-CRC cancer vaccines in which the D8-FAT1 epitope is used in combination with other CRC-specific antigens, including mutation-derived neoepitopes.

1 June 2009 in Journal of General Virology
Verified
Journal Article
Open access
JHJames Heather
James Heather
KFKirsty Flower
Kirsty Flower
SISamine Isaac
Samine Isaac
Alison SinclairAlison Sinclair
Alison Sinclair
Activation of the host gene egr1 is essential for the lytic replication of Epstein–Barr virus (EBV). egr1 is activated by Zta (BZLF1, ZEBRA). Zta interacts directly with DNA through a series of closely related Zta-response elements (ZREs). Here we dissect the mechanism used by Zta to interact with the egr1 promoter and identify a weak interaction with egr1ZRE that is dependent on the distal part of egr1ZRE. Furthermore, we demonstrate that the ability of Zta to interact with egr1ZRE is enhanced at least tenfold by methylation. The ability of Zta to transactivate a reporter construct driven by the egr1 promoter can be enhanced by methylation. As the ability of Zta to interact with a methylated ZRE in the EBV genome correlates with its ability to activate the expression of the endogenous viral gene BRLF1, this suggests that Zta may also have the capability to overturn epigenetic control of egr1.

1 November 2015 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
KLKin-Mei Leung
Kin-Mei Leung
SBSarah Batey
Sarah Batey
RRRobert Rowlands
Robert Rowlands
SISamine J Isaac
Samine J Isaac
PJPhil Jones
Phil Jones
HSHaijun Sun
Haijun Sun
Erratum to “A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis” Molecular Therapy November 01, 2015 In Brief Kin-Mei Leung, Sarah Batey, Robert Rowlands, Samine J Isaac, Phil Jones, Victoria Drewett, Joana Carvalho, Miguel Gaspar, Sarah Weller, Melanie Medcalf, Mateusz M Wydro, Robert Pegram, Geert C Mudde, Anton Bauer, Kevin Moulder, Max Woisetschläger, Mihriban Tuna, John S Haurum and Haijun Sun Full-Text PDF Open Archive

7 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ECELENA CAPRONI
ELENA CAPRONI
RCRiccardo Corbellari
Riccardo Corbellari
MTMichele Tomasi
Michele Tomasi
SISamine Jessica Isaac
Samine Jessica Isaac
STSilvia Tamburini
Silvia Tamburini
GGGuido Grandi
Guido Grandi
In situ vaccination (ISV) is a promising cancer immunotherapy strategy, consists in the intratumoral administration of immunostimulatory molecules (adjuvants). The rationale is that tumor antigens are abundant at the tumor site and therefore to elicit an effective anti-tumor immune response all is needed is an adjuvant, which can turn the immunosuppressive environment into an immunologically active one. Bacterial Outer Membrane Vesicles (OMVs) are potent adjuvants since they contain a number of microbe-associated molecular patterns (MAMPs) naturally present in the outer membrane and in the periplasmic space of Gram-negative bacteria. Therefore, they appear particularly indicted for ISV. In this work we first show that the OMVs from E. coli BL21(DE3)Δ60 strain promote a strong anti-tumor activity when intratumorally injected into the tumors of two different mouse models. Tumor inhibition correlates with a rapid infiltration of DCs and NK cells. We also show that the addition of neo-epitopes to OMVs synergizes with the vesicle adjuvanticity, as judged by a two-tumor mouse models. Overall, our data support the use of the OMVs in ISV and suggests that ISV efficacy could benefit from the addition of properly selected tumor-specific neo-antigens.